Court dismisses securities fraud lawsuit against Organogenesis, CEO and CFO with prejudice

Organogenesis Holdings Inc.

U.S. District Court for Eastern District of New York granted motion to dismiss on March 29, 2024.
All claims against Organogenesis, CEO, and CFO dismissed with prejudice, preventing refiling.
Lori Freedman, Chief Administrative and Legal Officer, expressed satisfaction with the ruling.
No financial impact or settlement amount disclosed in the announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.